Related Experiment Video

Updated: Jul 28, 2026

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

Cytochrome P450 CYP1B1 activity in renal cell carcinoma

M C E McFadyen1, W T Melvin, G I Murray

  • 1Department of Pathology, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK. m.mcfadyen@abdn.ac.uk

British Journal of Cancer
|July 29, 2004
PubMed

Insights

Active CYP1B1, an enzyme overexpressed in kidney cancer, was found in 70% of renal cell carcinoma (RCC) tumors. This enzyme metabolizes anticancer drugs, suggesting CYP1B1 as a potential therapeutic target for improving RCC treatment.

Area of Science:

  • Oncology
  • Biochemistry
  • Pharmacology

Background:

  • Renal cell carcinoma (RCC) is the most common kidney cancer with poor prognosis due to late detection and drug resistance.
  • Cytochrome P450 1B1 (CYP1B1) is a P450 enzyme overexpressed in various cancers and implicated in drug resistance.
  • Cytochrome P450 reductase (P450R) is essential for CYP1B1's metabolic activity.

Purpose of the Study:

  • To determine the expression and activity of CYP1B1 and P450R in normal kidney and RCC tissues.
  • To investigate the potential role of CYP1B1 in anticancer drug metabolism within RCC tumors.

Main Methods:

  • Expression analysis of CYP1B1 and P450R in 11 paired normal and tumor kidney samples, plus 15 additional tumor samples.
  • Measurement of CYP1B1 activity using the O-deethylation of ethoxyresorufin to resorufin.
  • Determination of P450R activity by monitoring cytochrome c reduction.

Main Results:

  • Active CYP1B1 was detected in 70% of RCC samples, with activity inhibited by the CYP1B1 inhibitor alpha-naphthoflavone.
  • No CYP1B1 activity was found in any of the examined normal kidney tissues.
  • Active P450R was present in all analyzed normal and tumor samples.

Conclusions:

  • The presence of active CYP1B1 in a majority of RCC tumors suggests its role in drug metabolism.
  • CYP1B1 represents a novel therapeutic target for intervention in renal cell carcinoma.
  • Understanding CYP1B1's role could lead to strategies to overcome anticancer drug resistance in RCC.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...